Special issue “The advance of solid tumor research in China”: Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors
- 7 October 2022
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 152 (1) , 90-99
Abstract
Clinically effective methods to predict the efficacy of sunitinib, for patients with metastatic or locally advanced pancreatic neuroendocrine tumors (panNET) are scarce, making precision treatment difficult. This study aimed to develop and validate a computed tomography (CT)‐based method to predict the efficacy of sunitinib in patients with panNET. Pretreatment CT images of 171 lesions from 38 patients with panNET were included. CT value ratio (CT value of tumor/CT value of abdominal aorta from the same patient) and radiomics features were extracted for model development. Receiver operating curve (ROC) with area under the curve (AUC) and decision curve analysis (DCA) were used to evaluate the proposed model. Tumor shrinkage of >10% at first follow‐up after sunitinib treatment was significantly associated with longer progression‐free survival (PFS; P < .001) and was used as the major treatment outcome. The CT value ratio could predict tumor shrinkage with AUC of 0.759 (95% confidence interval [CI], 0.685‐0.833). We then developed a radiomics signature, which showed significantly higher AUC in training (0.915; 95% CI, 0.866‐0.964) and validation (0.770; 95% CI, 0.584‐0.956) sets than CT value ratio. DCA also confirmed the clinical utility of the model. Subgroup analysis showed that this radiomics signature had a high accuracy in predicting tumor shrinkage both for primary and metastatic tumors, and for treatment‐naive and pretreated tumors. Survival analysis showed that radiomics signature correlated with PFS (P = .020). The proposed radiomics‐based model accurately predicted tumor shrinkage and PFS in patients with panNET receiving sunitinib and may help select patients suitable for sunitinib treatment.Keywords
Funding Information
- Guangzhou Municipal Science and Technology Project (201804010078)
- National Natural Science Foundation of China (82141104)
- Natural Science Foundation of Guangdong Province (2019A1515011373)
This publication has 17 references indexed in Scilit:
- Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?BMC Cancer, 2017
- Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society SystemsJournal of Clinical Oncology, 2017
- Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal CancerJournal of Clinical Oncology, 2016
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary SiteNeuroendocrinology, 2016
- Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursBritish Journal of Cancer, 2015
- ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor SyndromesNeuroendocrinology, 2012
- ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning TumorsNeuroendocrinology, 2012
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)Annals of Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009